Latest Governance Changes News

BSA Limited reported an 84% plunge in revenue for the half-year ending December 2025, driven by lost contracts and reduced volumes, yet managed a $6.3 million profit amid restructuring and cost controls. Significant board changes signal a strategic reset as the company navigates uncertain waters.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Cycliq Group Limited reported a 27% revenue decline for the half-year ending December 2025 but managed to return to profitability amid strategic platform upgrades and steady customer engagement.

Perpetual Credit Income Trust reported a robust half-year performance with a 50% jump in net assets to $802 million and an 8% rise in profit to $21 million, underpinned by a successful capital raising and steady distributions.

Taiton Resources has completed drilling at its Challenger West project and is preparing to drill at the Highway project's Yogi prospect, backed by a $2 million capital raise and a key board appointment.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

Otto Energy reported stable oil and gas production for the December quarter, supported by a strong cash position and strategic board changes. Despite a dip in oil prices, the company’s focus on cash flow and cost management positions it well for the year ahead.

Ioneer Ltd has reported a significant uplift in the economics of its Rhyolite Ridge lithium-boron project, alongside ongoing strategic partnership talks and strong market demand for lithium and boric acid.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

Aurelia Metals has delivered robust metal production and cash flow in Q2 FY26, reaffirming its full-year guidance while advancing key growth projects on schedule.